CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
3.370
+0.080 (2.43%)
Aug 25, 2026, 4:00 PM EDT - Market closed
CytomX Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, CytomX Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $12.25. The average 1-year stock price forecast is 263.50% higher than the current stock price, while the lowest is $6.00 (+78.04%) and the highest is $16 (+374.78%).
Price Target: $12.25 (+263.50%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for CytomX Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 5 | 5 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Maintains $11 | Buy | Maintains | $11 | +226.41% | Aug 17, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $12 | Buy | Reiterates | $12 | +256.08% | Aug 7, 2026 |
| Barclays | Barclays | Buy Maintains $16 | Buy | Maintains | $16 | +374.78% | Aug 7, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $15 → $14 | Buy | Maintains | $15 → $14 | +315.43% | Aug 7, 2026 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +226.41% | Jun 4, 2026 |
Financial Forecast
Revenue This Year
25.03M
from 76.20M
Decreased by -67.15%
Revenue Next Year
25.34M
from 25.03M
Increased by 1.24%
EPS This Year
-0.39
from -0.15
EPS Next Year
-0.47
from -0.39
EPS and Forward PE are based on non-GAAP adjusted numbers.